Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etravirine

FDA-approved product (tablet, oral), marketed as Etravirine, Intelence.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Etravirine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etravirine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etravirine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

    NCT05506605 · start 2022-12-12

    Registered record
    Registry ID
    NCT05506605
    Conditions
    HIV-1-infection
    Interventions
    Doravirine 100Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-12-12
    Completion
    2024-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDoravirine 100Mg Tab
    PhasePhase 4
    Registry statusUnknown

  • Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

    NCT04630002 · start 2020-10-28

    Registered record
    Registry ID
    NCT04630002
    Conditions
    HIV Infections
    Interventions
    GSK3640254; Darunavir/Ritonavir (DRV/RTV); Etravirine (ETR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-10-28
    Completion
    2021-10-02
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionGSK3640254; Darunavir/Ritonavir (DRV/RTV); Etravirine (ETR)
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Etravirine in Friedreich Ataxia Patients

    NCT04273165 · start 2020-09-17

    Registered record
    Registry ID
    NCT04273165
    Conditions
    Friedreich Ataxia
    Interventions
    Etravirine Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-09-17
    Completion
    2023-01-17
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFriedreich Ataxia
    InterventionEtravirine Tablets
    PhasePhase 2
    Registry statusCompleted

  • HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

    NCT04334551 · start 2020-06-23

    Registered record
    Registry ID
    NCT04334551
    Conditions
    HIV Infections
    Interventions
    Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06-23
    Completion
    2022-10-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDoravirine
    PhasePhase 4
    Registry statusUnknown

  • Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)

    NCT03369743 · start 2018-01-02

    Registered record
    Registry ID
    NCT03369743
    Conditions
    HIV Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-01-02
    Completion
    2019-12-30
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

    NCT03256422 · start 2017-09-07

    Registered record
    Registry ID
    NCT03256422
    Conditions
    HIV Infections
    Interventions
    Treatment discontinuation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-07
    Completion
    2020-03-02
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTreatment discontinuation
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

    NCT02818348 · start 2016-06

    Registered record
    Registry ID
    NCT02818348
    Conditions
    HIV-1 Infection
    Interventions
    darunavir/cobicistat; etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-11-23
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventiondarunavir/cobicistat; etravirine
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

    NCT02616029 · start 2015-12-17

    Registered record
    Registry ID
    NCT02616029
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-17
    Completion
    2019-07-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

    NCT02212379 · start 2015-01

    Registered record
    Registry ID
    NCT02212379
    Conditions
    HIV-1 Infection
    Interventions
    raltegravir and etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01
    Completion
    2018-04
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventionraltegravir and etravirine
    PhasePhase 2
    Registry statusCompleted

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

    NCT02063360 · start 2014-02-01

    Registered record
    Registry ID
    NCT02063360
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    BMS-663068; Darunavir (DRV); Ritonavir (RTV); Etravirine (ETR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02-01
    Completion
    2014-05-13
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionBMS-663068; Darunavir (DRV); Ritonavir (RTV); Etravirine (ETR)
    PhasePhase 1
    Registry statusCompleted

  • Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

    NCT02016924 · start 2014-01-16

    Registered record
    Registry ID
    NCT02016924
    Conditions
    Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
    Interventions
    ATV; DRV; Cobicistat; BR; F/TAF; LPV/r; Third Unboosted Drug; Cobicistat TOS; F/TAF TOS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2014-01-16
    Completion
    2027-03
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome (AIDS); HIV Infections
    InterventionATV; DRV; Cobicistat; BR +5 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

    NCT01741844 · start 2012-09

    Registered record
    Registry ID
    NCT01741844
    Conditions
    Acquired Immune Deficiency Syndrome
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-07
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

    NCT01615601 · start 2011-10

    Registered record
    Registry ID
    NCT01615601
    Conditions
    Human Immunodeficiency Virus (HIV)
    Interventions
    darunavir (PREZISTA); etravirine (INTELENCE); ritonavir; Other antiretroviral medications
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-10
    Completion
    2013-04
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)
    Interventiondarunavir (PREZISTA); etravirine (INTELENCE); ritonavir; Other antiretroviral medications
    PhaseNot recorded
    Registry statusCompleted